Compare Fresenius Kabi Onco. with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs WOCKHARDT - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. WOCKHARDT FRESENIUS KABI ONCO./
WOCKHARDT
 
P/E (TTM) x 22.1 -22.2 - View Chart
P/BV x 3.1 1.2 266.2% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 FRESENIUS KABI ONCO.   WOCKHARDT
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
WOCKHARDT
Mar-18
FRESENIUS KABI ONCO./
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs1761,012 17.4%   
Low Rs79532 14.8%   
Sales per share (Unadj.) Rs37.7355.9 10.6%  
Earnings per share (Unadj.) Rs5.1-60.3 -8.4%  
Cash flow per share (Unadj.) Rs6.7-46.8 -14.4%  
Dividends per share (Unadj.) Rs00.01 0.0%  
Dividend yield (eoy) %00 0.0%  
Book value per share (Unadj.) Rs42.5257.8 16.5%  
Shares outstanding (eoy) m158.23110.63 143.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.42.2 155.7%   
Avg P/E ratio x25.0-12.8 -195.1%  
P/CF ratio (eoy) x18.9-16.5 -114.7%  
Price / Book Value ratio x3.03.0 99.9%  
Dividend payout %00 0.0%   
Avg Mkt Cap Rs m20,13585,379 23.6%   
No. of employees `0001.26.3 18.4%   
Total wages/salary Rs m7039,371 7.5%   
Avg. sales/employee Rs Th5,176.26,295.0 82.2%   
Avg. wages/employee Rs Th610.41,498.3 40.7%   
Avg. net profit/employee Rs Th699.6-1,066.3 -65.6%   
INCOME DATA
Net Sales Rs m5,96339,369 15.1%  
Other income Rs m181,202 1.5%   
Total revenues Rs m5,98140,571 14.7%   
Gross profit Rs m1,43018 7,814.8%  
Depreciation Rs m2581,495 17.2%   
Interest Rs m-262,555 -1.0%   
Profit before tax Rs m1,216-2,830 -43.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-68-3,582 1.9%   
Tax Rs m342257 133.2%   
Profit after tax Rs m806-6,669 -12.1%  
Gross profit margin %24.00 51,594.7%  
Effective tax rate %28.1-9.1 -309.8%   
Net profit margin %13.5-16.9 -79.8%  
BALANCE SHEET DATA
Current assets Rs m5,10233,796 15.1%   
Current liabilities Rs m2,38526,917 8.9%   
Net working cap to sales %45.617.5 260.7%  
Current ratio x2.11.3 170.3%  
Inventory Days Days15079 189.1%  
Debtors Days Days11389 127.0%  
Net fixed assets Rs m5,14839,664 13.0%   
Share capital Rs m158553 28.6%   
"Free" reserves Rs m6,55627,968 23.4%   
Net worth Rs m6,73228,522 23.6%   
Long term debt Rs m95221,731 4.4%   
Total assets Rs m10,38881,620 12.7%  
Interest coverage x-45.8-0.1 42,575.7%   
Debt to equity ratio x0.10.8 18.6%  
Sales to assets ratio x0.60.5 119.0%   
Return on assets %7.5-5.0 -149.0%  
Return on equity %12.0-23.4 -51.2%  
Return on capital %14.6-7.7 -190.3%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,2989,807 54.0%   
Fx outflow Rs m1,7721,789 99.1%   
Net fx Rs m3,5258,019 44.0%   
CASH FLOW
From Operations Rs m1,274684 186.2%  
From Investments Rs m-1,2046,302 -19.1%  
From Financial Activity Rs m-196-7,695 2.5%  
Net Cashflow Rs m-126-664 19.0%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 2.3 13.0%  
FIIs % 9.6 7.7 124.7%  
ADR/GDR % 0.0 0.1 -  
Free float % 9.1 15.4 59.1%  
Shareholders   42,599 67,757 62.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  CADILA HEALTHCARE  GSK PHARMA  PANACEA BIOTECH  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (3QFY19); Net Profit Down 80.6% (Quarterly Result Update)

Jan 29, 2019 | Updated on Jan 29, 2019

For the quarter ended December 2018, WOCKHARDT LTD. has posted a net profit of Rs 769 m (down 80.6% YoY). Sales on the other hand came in at Rs 10 bn (up 4.0% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (2QFY19); Net Profit Down 158.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, WOCKHARDT LTD. has posted a net profit of Rs 228 m (down 158.2% YoY). Sales on the other hand came in at Rs 11 bn (up 10.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (1QFY19); Net Profit Down 81.4% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, WOCKHARDT LTD. has posted a net profit of Rs 862 m (down 81.4% YoY). Sales on the other hand came in at Rs 10 bn (up 13.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS